• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
COVID-19 and Women’s Health

43 Pregnant Women with COVID-19: Clinical Course and Outcomes

image_pdfFavoriteLoadingFavorite

PURPOSE:

Breslin et al. (AJOG MFM, 2020) provide follow-up on 43 pregnant women with confirmed SARS-CoV-2 infection.

METHODS:

  • Retrospective review (March 13 to March 27, 2020)
    • 2 Affiliated hospitals in New York City
  • Participants
    • Pregnant women with confirmed SARS-C0V-2 infection (nasopharyngeal swab)
    • Diagnosed in triage or direct L&D admission
  • Study design
    • Initially, pregnant women were screened if they were symptomatic
    • March 22, universal COVID-19 screening was initiated for women admitted to L&D unit
    • Medical records of mothers and newborns were reviewed
  • Women were divided in to 2 cohorts for reporting outcomes
    • Symptomatic presentation
    • Asymptomatic | Identified via viral screening

RESULTS:

Maternal Results

  • 43 pregnant patients
    • Obesity: 60.5% | 2 women had BMI >40
    • Most common comorbidity: Asthma: 18.6% (n=8)
    • Additional comorbidities: Type 2 diabetes | Chronic hypertension
    • Severity: Mild disease (nonpneumonia and mild pneumonia): 86% | Severe disease: 9.3% | Critical: 4.7%

Symptomatic: 67.4% (n=29)

  • Mild disease: 90% (n=26)
    • Outpatient management at time of publication: 22 patients
    • Admitted for Ob management: 4 patients (term labor, preterm labor, IOL, term PROM)
  • Severe disease leading to antenatal admission: 10.3% (n=3)
    • 1 patient treated with hydroxychloroquine | 1 patient treated with IV hydration | 1 patient treated with ceftriaxone and azithromycin (suspected bacterial pneumonia)
  • Postpartum admission 6 days post successful IOL with severe disease: 3% (n=1)
    • Severe disease treated with hydroxychloroquine

Asymptomatic: 32.6% (n=14)

  • COVID-19 symptom development: 71.4% (n=10)
  • 2 of the 10 patients who became symptomatic required ICU admission: 1 patient discharged, and 1 patient was an inpatient at time of publication

Neonatal Results

  • 18 infants
    • All had normal Apgars
    • None were positive for SARS-CoV-2 infection
    • None were positive for IgG or IgM
    • All discharged home at time of publication
  • NICU admission
    • Prematurity (34w6d) | Multicystic dysplastic kidney (term) | Respiratory distress/sepsis
  • “Healthy newborns either roomed in with their mothers in isolettes whenever possible or were cared for in an isolated nursery for babies of COVID-positive mothers throughout their stay”
    • Breastfeeding encouraged with maternal masking and hand hygiene

CONCLUSION:

  • Significant percentage of women were asymptomatic on presentation to triage and L&D, supporting the use of universal testing prior to L&D admission
  • Pattern of disease severity matches previous reports in nonpregnant individuals
    • Large series from China in JAMA (see ‘Learn More – Primary Sources’ below): Mild: 81% | Severe: 14% | Critical: 5%
  • Authors recommend COVID-19 infection should be included in the differential when previous asymptomatic patients develop postoperative infections
  • In reference to the use of hydroxychloroquine and other medications, the authors state

Despite these women having similar objective findings, they received different treatments after consultation with the infectious disease specialists, likely due to nuances in their clinical characteristics and evolving recommendations

Learn More – Primary Sources:

COVID-19 infection among asymptomatic and symptomatic pregnant women: Two weeks of confirmed presentations to an affiliated pair of New York City hospitals

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China (JAMA, 2020)

Get COVID-19 Research Summaries Direct to Your Phone, with ObGFirst

Try it Free »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 and Women’s Health Posts
Next >

Related ObG Topics:

ACOG COVID-19 FAQs for Obstetrical Care
U.S. COVID-19 PRIORITY Pregnancy Registry Now Open
COVID-19 and Pregnancy: Literature Review and Comparisons to SARS and MERS
Clinical Characteristics of Pregnant Women with COVID-19 Pneumonia

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site